Table 3. Current clinical trials on HDAC inhibitors in GBM.
| HDAC inhibitor | Chemotherapeutic or biological agents | Radiation therapy (RT) |
Type of malignancy | Phase | Trial identifier | |
|---|---|---|---|---|---|---|
| Valproic acid | Temozolomide | RT | GBM that has not been previously treated with chemotherapy or radiation | 2 | NCT00302159 | |
| Vorinostat | - | - | Progressive or recurrent glioblastoma | 2 | NCT00238303 | |
| Temozolomide | - | Malignant glioma: glioblastoma | 1 | NCT00268385 | ||
| Temozolomide | RT | Newly diagnosed glioblastoma | 1,2 | NCT00731731 | ||
| Temozolomide + isotretinoin |
- | Recurrent glioblastoma | 1,2 | NCT00555399 | ||
| Bortezomib | - | Progressive, recurrent glioblastoma | 2 | NCT00641706 | ||
| Bevacizumab | - | Recurrent glioblastoma | 2 | NCT01738646 | ||
| Temozolomide + bevacizumab |
- | Recurrent glioblastoma | 1,2 | NCT00939991 | ||
| Bevacizumab + irinotecan |
- | Recurrent glioblastoma | 1 | NCT00762255 | ||
| Belinostat | Temozolomide | RT | Newly diagnosed glioblastoma | 2 | NCT02137759 | |
| Romidepsin | - | - | Recurrent high grade gliomas: glioblastoma | 1,2 | NCT00085540 | |